Vaccine company Valneva SE (Nasdaq:VALN) (Euronext Paris:VLA) on Wednesday announced positive Phase 2 results for its Lyme disease vaccine candidate, VLA15.
Data showed a strong anamnestic immune response and a favourable safety profile following a third annual booster dose in children and adults.
The results demonstrated significant antibody responses across all six serotypes, with 100% seroconversion rates reported in all age groups. Safety and tolerability remained consistent with previous boosters, with no concerns raised by the independent Data Monitoring Committee.
VLA15 remains the most advanced Lyme disease vaccine in development, with two Phase 3 trials ongoing. Vaccination in these studies has been completed and, subject to favourable results, Pfizer (NYSE:PFE) aims to file regulatory applications with the US Food and Drug Administration and the European Medicines Agency in 2026.
According to the Centers for Disease Control and Prevention, Lyme disease affects around 476,000 people annually in the United States, with 132,000 reported cases in Europe. VLA15 is being studied in both adults and children across endemic regions in North America and Europe.
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD
Amneal's risperidone extended-release injectable suspension approved by US FDA
Brain+ pilot shows Ayla therapy boosts cognitive outcomes in dementia care
Ascelia Pharma files NDA with FDA for liver imaging drug Orviglance
Biophytis secures EMA clearance to advance Phase 2 obesity trial
Valneva reports strong Phase 2 booster results for Lyme disease vaccine candidate VLA15
Eisai begins rolling sBLA to US FDA for initiation dosing of LEQEMBI IQLIK
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
BeOne Medicines reports positive topline data for sonrotoclax in mantle cell lymphoma
Cinclus Pharma to launch Phase III trial of linaprazan glurate in erosive GERD